AbbVie’s Gonzalez Sounds Alarm On US Drug Price Negotiation Proposal

 
• By Joseph Haas

AbbVie posts solid quarter on strength of Skyrizi growth and continued US growth for Humira ahead of patent expiry. Imbruvica revenue continues to decline, however.

US drug costs: Medical capsules spilled out of an open capsule on dollar bills. High costs of expensive medication concept
AbbVie's CEO joins the charge opposing Congress's drug price negotiation proposal

More from Earnings

More from Business